Depreciation of Verve Therapeutics, Inc. from 31 Dec 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Verve Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2019 to 31 Mar 2025.
  • Verve Therapeutics, Inc. Depreciation for the quarter ending 31 Mar 2025 was $1,716,000, a 5.1% increase year-over-year.
  • Verve Therapeutics, Inc. Depreciation for the twelve months ending 31 Mar 2025 was $6,837,000, a 15% increase year-over-year.
  • Verve Therapeutics, Inc. annual Depreciation for 2024 was $6,753,000, a 24% increase from 2023.
  • Verve Therapeutics, Inc. annual Depreciation for 2023 was $5,455,000, a 95% increase from 2022.
  • Verve Therapeutics, Inc. annual Depreciation for 2022 was $2,804,000, a 83% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Verve Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $6,837,000 $1,716,000 +$84,000 +5.1% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $6,753,000 $1,700,000 +$183,000 +12% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $6,570,000 $1,754,000 +$280,000 +19% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $6,290,000 $1,667,000 +$330,000 +25% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $5,960,000 $1,632,000 +$505,000 +45% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $5,455,000 $1,517,000 +$592,000 +64% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $4,863,000 $1,474,000 +$757,000 +106% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $4,106,000 $1,337,000 +$689,000 +106% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $3,417,000 $1,127,000 +$613,000 +119% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $2,804,000 $925,000 +$502,000 +119% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $2,302,000 $717,000 +$305,000 +74% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $1,997,000 $648,000 +$248,000 +62% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,749,000 $514,000 +$214,000 +71% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $1,535,000 $423,000 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $412,000 -$188,000 -31% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $400,000 +$100,000 +33% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $300,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $600,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $300,000 01 Apr 2020 30 Jun 2020 10-Q/A 16 Aug 2021 2021 Q2

Verve Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,753,000 +$1,298,000 +24% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $5,455,000 +$2,651,000 +95% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $2,804,000 +$1,269,000 +83% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $1,535,000 +$207,000 +16% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $1,328,000 +$1,228,000 +1228% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $100,000 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.